RxDoctor Payments Data

James Gentry

Nuclear Cardiology · Nashville, TNNPI 1912297144

Payments from drug & device makers

$36,456in general payments, 2019–2025

Across 301 payments — averaging $121.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • E.r. Squibb & Sons, L.L.C.$27K
  • Abbott$3K
  • Heartflow, Inc.$2K
  • Edwards Lifesciences$659
  • Pfizer$616
  • Boston Scientific$614
  • plus $3K from 22 others

What the payments were for

  • Consulting fees$1,3884%
  • Speaking & faculty fees$26,79273%
  • Travel & lodging$8462%
  • Food & beverage$7,43120%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few nuclear cardiology providers in Tennesseeto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$160,610
Medicare patients
1,225
Services billed
2,729

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban145$145,294
CamzyosMavacamten13$104,551
EntrestoSacubitril/Valsartan29$44,994
XareltoRivaroxaban35$32,114
Repatha SureclickEvolocumab30$24,973
Praluent PenAlirocumab12$12,883
JardianceEmpagliflozin17$9,828
Repatha SyringeEvolocumab13$7,115
Atorvastatin Calcium155$1,605
Propranolol Hcl ErPropranolol Hcl12$1,525
Metoprolol Succinate75$1,435
Ezetimibe28$1,216
Rosuvastatin Calcium99$1,021
Carvedilol70$1,015
Pravastatin Sodium21$709

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$616$145,294145 claims
E.r. Squibb & Sons, L.L.C.Camzyos$26,988$104,55113 claims
NovartisEntresto$32$44,99429 claims
Johnson & JohnsonXarelto$313$32,11435 claims
Boehringer IngelheimJardiance$218$9,82817 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few nuclear cardiology providers in Tennesseeon file to place this against a meaningful peer group, so we don't.

Other nuclear cardiology in Nashville

Where these figures come from

Is this you, or does something look wrong? →